BI 1516-0003

Have you been diagnosed with borderline personality disorder or ADHD?

The BI 1515-0003 study is investigating the tolerability of the drug BI 3031185 in people with borderline personality disorder (BPD) or attention deficit/hyperactivity disorder (ADHD) and also aims to find out whether the drug can help people with BPD and ADHD. BI 3031185 is a drug developed for the treatment of people with certain mental illnesses such as BPD and ADHD.

• Patients with borderline personality disorder or ADHD 
• Aged between 18 and 45 years 
• Willingness to abstain from alcohol for 24 hours and all other drugs, including cannabis, for 72 hours prior to visits 2 and 3 
• Willingness to abstain from alcohol and cannabis for 72 hours after taking the study drug and to abstain from all other mind-altering recreational drugs for the duration of the study 
• Willingness to abstain from prescribed psychostimulants prescribed for the treatment of BPS/ADHD for 72 hours prior to visits 2 and 3 and 24 hours after taking the study medication

To test the tolerability of the drug, a comparison with a dummy drug, also known as a placebo, is carried out. The placebo looks like the study drug but does not contain any active ingredient. 

• Arrival the day before, examinations take place, dinner included 
• The next day, medication is taken after breakfast and further examinations are carried out 
• Afterwards, stay at the study center for one night 
• Two appointments with overnight stays 14 days apart (once with placebo, once with study medication) 

In total, the study takes about two months, including preliminary and follow-up examinations. 

Your contribution can provide physicians and researchers with new insights into the treatment of BPS and ADHD with BI 3031185.  

For further information and if you are interested in participating in a study, simply fill out our contact form. You can also contact us by email at . 

You can find further information on this flyer.